Linked Life Data

16954440

Source:http://linkedlifedata.com/resource/pubmed/id/16954440

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2006-9-6
pubmed:abstractText
The purpose of this study is to investigate the role of carbonic anhydrase IX (CAIX) expression in predicting the response to epirubicin and disease-free survival (DFS) in breast cancer patients enrolled in a single institution trial of primary anthracycline and tamoxifen therapy. CAIX expression was assessed in 183 patients with T2-4 N0-1 breast cancer enrolled in a randomized trial comparing four cycles of single agent epirubicin versus epirubicin+tamoxifen as primary systemic treatment. All patients received postoperatively four cycles of the four weekly i.v. cyclophosphamide, methotrexate, 5-fluorouracil regimen. Patients with estrogen receptor (ER)-positive primary tumors received 5 years of adjuvant tamoxifen. Pretreatment, p53 (P=0.007), c-erbB2 (P<0.01), and Ki67 (P=0.02) were directly associated with CAIX expression, while bcl2 (P<0.000) and ER (P=0.000) and progesterone receptor (PgR; P<0.01) were inversely correlated. In multivariate analysis, only high p53 and low bcl2 were independently associated with CAIX positivity. CAIX immunostaining was significantly associated with poor outcome for DFS (P<0.002) and overall survival (P=0.001). In multivariate analysis, a significant interaction was found between CAIX and markers of hormone sensitivity, bcl2 (P=0.01), ER (P=0.02), PgR (P=0.02), and lymph node involvement (P=0.04), in predicting DFS. Presently, there are few clinical markers of resistance to tamoxifen treatment in ER-positive tumors. CAIX expression in breast cancer patients shows a negative predictive role of treatment efficacy in ER-positive patients on the adjuvant tamoxifen after primary chemo-endocrine therapy. Studies investigating the effects of pH on tamoxifen uptake and the effects of therapy with CA inhibitors are planned.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
1351-0088
pubmed:author
pubmed:issnType
Print
pubmed:volume
13
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
921-30
pubmed:meshHeading
pubmed-meshheading:16954440-Antibiotics, Antineoplastic, pubmed-meshheading:16954440-Antigens, Neoplasm, pubmed-meshheading:16954440-Antineoplastic Agents, Hormonal, pubmed-meshheading:16954440-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:16954440-Biopsy, pubmed-meshheading:16954440-Breast Neoplasms, pubmed-meshheading:16954440-Carbonic Anhydrases, pubmed-meshheading:16954440-Disease-Free Survival, pubmed-meshheading:16954440-Epirubicin, pubmed-meshheading:16954440-Female, pubmed-meshheading:16954440-Gene Expression Regulation, Neoplastic, pubmed-meshheading:16954440-Humans, pubmed-meshheading:16954440-Immunohistochemistry, pubmed-meshheading:16954440-Neoplasm Metastasis, pubmed-meshheading:16954440-Neoplasm Staging, pubmed-meshheading:16954440-Postmenopause, pubmed-meshheading:16954440-Premenopause, pubmed-meshheading:16954440-Receptors, Estrogen, pubmed-meshheading:16954440-Survival Analysis, pubmed-meshheading:16954440-Tamoxifen, pubmed-meshheading:16954440-Treatment Outcome
pubmed:year
2006
pubmed:articleTitle
Role of carbonic anhydrase IX expression in prediction of the efficacy and outcome of primary epirubicin/tamoxifen therapy for breast cancer.
pubmed:affiliation
Weatherall Molecular Oncology Laboratories, Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford OX3 9DS, UK.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't